Artiva Biotherapeutics, Inc.
$10.32 +$0.29 (+2.89%) 1D After hoursKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 23
2 insider transaction filings hit the record.
Form 4s are events, not verdicts — officers, directors, and 10% owners reporting their own trades. The forms post hours before the media writes them up.
RECEIPT: SEC FORM 4 × 2, TIMESTAMPED -
Jul 22
A material event was filed (Form 8-K).
8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
RECEIPT: SEC FORM 8-K, TIMESTAMPED -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Jun 8
From its Apr 20 high, the share price fell 49%.
Peak close $13.39 on Apr 20; trough close $6.80 on Jun 8. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -49% -
Apr 16
The stock moved +33.1% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Apr 16 -
Apr 15
The stock moved +21.5% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Apr 15
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.